Study to Learn the Effect of Drug BAY1817080 on the Way the Body Absorbs, Distributes and Excretes Another Drug Rosuvastatin in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

March 2, 2020

Primary Completion Date

August 29, 2020

Study Completion Date

December 7, 2020

Conditions
Drug Interactions
Interventions
DRUG

Rosuvastatin

Single dose of 5 mg rosuvastatin is administered as tablet orally on Day 1 of Period 1 (total length = 5 days).

DRUG

Rosuvastatin + BAY1817080

A single dose of 5 mg rosuvastatin tablets is administered on Day 8 of Period 2 (total length = 15 days). BAY1817080 is administered as tablets twice daily on Days 1 to 14 of Period 2.

Trial Locations (1)

32117

Covance Clinical Research Unit, Inc., Daytona Beach

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY